USPTO serial 86591321
VERNALIS
Reviewed by CopyMark Law Group
Reg. 4891901Status 710
- Filing date
- Status date
- Registration date
- Jan 26, 2016
- Examiner
- STRINGER, DANIEL
- Law office
- —
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with VERNALIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge, GB
CAMBRIDGE, GB
Berkshire, GB
Berkshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mainak H. Mehta
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP525 B. Street, Suite 2200San Diego, CA 92101UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceutical and veterinary preparations for the treatment and prophylaxis of infections by a bacterial, viral or fungal agent in skin infections, infections of major organs, ear, nose and throat infections, respiratory infections, subcutaneous infections, blood infections, cerebral infections and sexually transmitted infections, neurological and psychological disorders, nervous system diseases and disorders, migraines, headaches, coughs, colds, allergies and respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, organ damage, cell proliferation, blood disorders, pain, cancers, women's health issues in the nature of medical conditions relating to reproduction disorders, conception disorders, pregnancy and contraception disorders, menstrual disorders, post-menopausal disorders, sexual function disorders, female hormone disorders, osteoporosis and breast cancer, uterine and ovarian cancer, men's health issues in the nature of reproduction disorders, conception disorders, contraception disorders, prostate disorders, testes disorders, male hormone disorders, alopecia, sexual function disorders, prostate cancer, testicular cancer and impotence, endocrinology disorders, pediatrics issues in the nature of mental health disorders, diabetes and endocrinology disorders, gastroenterology disorders, herpetology disorders, immunology disorders, skin infections, and allergies, nephology disorders, neurodisability disorders, neurology disorders, oncology disorders, respiratory disorders, rheumatology disorders, dermatology disorders, cardiology disorders, geriatrics issues in the nature of clinical, preventative, remedial and social aspects of illness in the elderly in the nature of immobility disorders, incontinence disorders, mental health disorders, strokes, heart disease, infectious diseases, diabetes, delirium, syncope, cerebral aging and Parkinsonism, and inflammation disorders; Sanitary preparations for medical purposes; Dietetic food and substances for medical or veterinary use in the nature of pasta, breads, cereals, crackers, meat, fruit, vegetables, confectionery, lipids in the nature of margarine, butter substitute, lard, fish oil, butter, peanut oil, soya bean oil, sunflower oil, sesame oil, coconut oil, olive oil, animal-derived fats and oils, plant-derived oils and dairy products in the nature of cheese, milk, butter, yoghurt, cream, and curds, all adapted for medical use; dietary supplements for humans and animals; chemical reagents for medical or veterinary purposes; chemical medical reagents for therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for the treatment and prophylaxis of infections by a bacterial, viral or fungal agent in skin infections, infections of major organs, ear, nose and throat infections, respiratory infections, subcutaneous infections, blood infections, cerebral infections and sexually transmitted infections, neurological and psychological disorders, nervous system diseases and disorders, migraines, headaches, coughs, colds, allergies and respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, organ damage, cell proliferation, blood disorders, pain, cancers, women's health issues in the nature of medical conditions relating to reproduction disorders, conception disorders, pregnancy and contraception disorders, menstrual disorders, post-menopausal disorders, sexual function disorders, female hormone disorders, osteoporosis and breast cancer, uterine and ovarian cancer, men's health issues in the nature of reproduction disorders, conception disorders, contraception disorders, prostate disorders, testes disorders, male hormone disorders, alopecia, sexual function disorders, prostate cancer, testicular cancer and impotence, endocrinology disorders, pediatrics issues in the nature of mental health disorders, diabetes and endocrinology disorders, gastroenterology disorders, herpetology disorders, immunology disorders, skin infections, and allergies, nephology disorders, neurodisability disorders, neurology disorders, oncology disorders, respiratory disorders, rheumatology disorders, dermatology disorders, cardiology disorders, geriatrics issues in the nature of clinical, preventative, remedial and social aspects of illness in the elderly in the nature of immobility disorders, incontinence disorders, mental health disorders, strokes, heart disease, infectious diseases, diabetes, delirium, syncope, cerebral aging and Parkinsonism, and inflammation disorders; medical chemical preparations for the treatment and prophylaxis of infections by a bacterial, viral or fungal agent in skin infections, infections of major organs, ear, nose and throat infections, respiratory infections, subcutaneous infections, blood infections, cerebral infections and sexually transmitted infections, neurological and psychological disorders, nervous system diseases and disorders, migraines, headaches, coughs, colds, allergies and respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, organ damage, cell proliferation, blood disorders, pain, cancers, women's health issues in the nature of medical conditions relating to reproduction disorders, conception disorders, pregnancy and contraception disorders, menstrual disorders, post-menopausal disorders, sexual function disorders, female hormone disorders, osteoporosis and breast cancer, uterine and ovarian cancer, men's health issues in the nature of reproduction disorders, conception disorders, contraception disorders, prostate disorders, testes disorders, male hormone disorders, alopecia, sexual function disorders, prostate cancer, testicular cancer and impotence, endocrinology disorders, pediatrics issues in the nature of mental health disorders, diabetes and endocrinology disorders, gastroenterology disorders, herpetology disorders, immunology disorders, skin infections, and allergies, nephology disorders, neurodisability disorders, neurology disorders, oncology disorders, respiratory disorders, rheumatology disorders, dermatology disorders, cardiology disorders, geriatrics issues in the nature of clinical, preventative, remedial and social aspects of illness in the elderly in the nature of immobility disorders, incontinence disorders, mental health disorders, strokes, heart disease, infectious diseases, diabetes, delirium, syncope, cerebral aging and Parkinsonism, and inflammation disorders; medicines for the treatment and prophylaxis of infections by a bacterial, viral or fungal agent in skin infections, infections of major organs, ear, nose and throat infections, respiratory infections, subcutaneous infections, blood infections, cerebral infections and sexually transmitted infections, neurological and psychological disorders, nervous system diseases and disorders, migraines, headaches, coughs, colds, allergies and respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, organ damage, cell proliferation, blood disorders, pain, cancers, women's health issues in the nature of medical conditions relating to reproduction disorders, conception disorders, pregnancy and contraception disorders, menstrual disorders, post-menopausal disorders, sexual function disorders, female hormone disorders, osteoporosis and breast cancer, uterine and ovarian cancer, men's health issues in the nature of reproduction disorders, conception disorders, contraception disorders, prostate disorders, testes disorders, male hormone disorders, alopecia, sexual function disorders, prostate cancer, testicular cancer and impotence, endocrinology disorders, pediatrics issues in the nature of mental health disorders, diabetes and endocrinology disorders, gastroenterology disorders, herpetology disorders, immunology disorders, skin infections, and allergies, nephology disorders, neurodisability disorders, neurology disorders, oncology disorders, respiratory disorders, rheumatology disorders, dermatology disorders, cardiology disorders, geriatrics issues in the nature of clinical, preventative, remedial and social aspects of illness in the elderly in the nature of immobility disorders, incontinence disorders, mental health disorders, strokes, heart disease, infectious diseases, diabetes, delirium, syncope, cerebral aging and Parkinsonism, and inflammation disorders ] | SECTION 8 - CANCELLED | — |
| 042 | Scientific and technological services, namely, pharmaceutical product evaluation, development and testing services; industrial analysis and research services in the nature of pharmaceutical product evaluation, development and testing services; biotechnology research; chemical research; research consulting in the field of pharmaceutical product evaluation, development and testing services; scientific, medical and clinical research and development in the nature of pharmaceutical product evaluation, development and testing services; research and development in the nature of pharmaceutical product evaluation, development and testing services; laboratory research services relating to pharmaceuticals; pharmaceutical research; medical and scientific laboratory services; laboratory testing services in the field of pharmaceutical product evaluation, development and testing services; testing of pharmaceuticals; chemical analysis; technological research in the nature of pharmaceutical product evaluation, development and testing services; conducting product evaluations in the field of new pharmaceuticals; inspection of pharmaceuticals; pharmaceutical product evaluation; pharmaceutical drug development services | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Vernalis Development Limited
- Other trademarks owned by VERNALIS (R&D) LIMITED
- Other trademarks owned by Vernalis Development Limited
- Other trademarks owned by Vernalis Development Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named VERNALIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 7, 2026 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Jan 26, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Jun 10, 2022 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jun 10, 2022 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jun 10, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 21, 2021 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Aug 16, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 16, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 16, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 16, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 16, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 30, 2021 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 16, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 19, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 19, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 19, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 19, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 19, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 26, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 26, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 10, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 10, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 21, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 5, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 2, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 1, 2015 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 1, 2015 | ALIE | ASSIGNED TO LIE | — |
| Oct 1, 2015 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 1, 2015 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 1, 2015 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 25, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 25, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 25, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 4, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 3, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 3, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 23, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 23, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 23, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 15, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 16, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 11, 2015 | NWAP | NEW APPLICATION ENTERED | — |